The RxSight Light Adjustable Lens (LAL) is the first and only intraocular lens that enables postoperative refractive customisation. Using targeted UV light treatments after surgery, the non-diffractive lens can be adjusted to refine refractive outcomes while preserving contrast sensitivity and minimising dysphotopsias.
The LAL is designed to deliver laser-assisted in situ keratomileusis-like visual outcomes1,2 and is well suited to patients who have previously undergone refractive surgery.3 It also enables precise blended vision outcomes, is available in spherical powers from -2.0 D to 30.0 D and can correct as little as 0.5 D of astigmatism. In a bilateral implantation study,4 93% of patients achieved uncorrected distance vision of 6/6 or better, while 94% achieved J2 (N6) near vision or better at best focus.
Contact: globalmarketing@rxsight.com
References
- RxSight Inc. P160055: FDA summary of safety and effectiveness data. Aliso Viejo (CA): RxSight Inc.; 2017.
- Sandoval HP, Donnenfeld ED, Kohnen T, et al. Modern laser in situ keratomileusis outcomes. J Cataract Refract Surg. 2016;42(8):1224-34. doi: 10.1016/j.jcrs.2016.07.012.
- Wong JR, Folden DV, Johnson R, et al. Visual outcomes of a second-generation, enhanced UV-protected light adjustable lens in cataract patients with previous LASIK and/or PRK. Clin Ophthalmol. 2023;17:3379-87. doi: 10.2147/OPTH.S432457.
- Schallhorn JM, Rajanala A. Clinical outcomes of patients bilaterally implanted with the light adjustable lens: Results of a Phase IV Clinical Registry. J Cataract Refract Surg. 2026 Jun 16. doi: 10.1097/j.jcrs.0000000000001994.
